Integrated DNA Technologies (IDT) now provides continuous oligonucleotide (oligo) synthesis from early design to commercial scale, allowing minimum residual disease (MRD) and multi-cancer early detection (MCED) diagnostics programs to avoid the operational risk of switching suppliers mid-development. To support continuous development-to-scale delivery, IDT added low-yield, high-diversity oligo production to its established high-yield manufacturing.
Key Insights: CDMOs supporting oncology diagnostics programs face a recurring supply-chain bottleneck: Custom oligo synthesis services capable of producing high-diversity research panels quickly often cannot scale to the volume, consistency, and documentation standards that commercial MRD or MCED assay programs require. The result is a forced mid-development supplier switch that triggers revalidation, re-qualification, and potential regulatory review. IDT targets this handoff problem directly, warranting evaluation by procurement and QA teams managing oligo supply continuity for regulated programs.
What Compliance Gap Does End-to-End Oligo Synthesis Address?
Regulated genomics programs require oligo synthesis services that demonstrate consistent yield quality, purity, and sequence fidelity throughout a program’s lifecycle. Three compliance pressures make supplier continuity a procurement priority:
- CMC Consistency: FDA guidelines for oligonucleotide therapeutics establish manufacturing consistency as a core CMC commitment across a program’s development arc.
- Audit Exposure: Mid-program supplier transitions create revalidation obligations and audit exposure under applicable GMP frameworks.
- The Diversity/Purity Tradeoff: Pools containing thousands of unique sequences must meet sequencing-grade purity standards; genetics and genomic testing labs historically had to accept lower consistency in early development or over-specify at research scale, neither of which supports efficient investigational new drug (IND) submissions.
IDT’s Expansion Provides a Single-Supplier Oligo Ecosystem
IDT’s expansion provides a single-supplier ecosystem featuring a new rapid-innovation pilot lab, tripled high-yield manufacturing capacity, and integrated low-yield oligo production
| Capability | Application | Regulatory/Accreditation Relevance |
| Low-Yield, High-Diversity Synthesis | MRD panel development, MCED library design, Early-phase NGS probe creation | Supports rapid iteration under the FDA IND CMC requirements |
| High-Yield, High-Fidelity Synthesis | Commercial assay oligos, GMP clinical trial material | ISO 13485:2016 Compliant; Supports FDA CMC documentation for oligo drug products and diagnostic reagent programs |
| Single-Supplier Continuity | Programs scaling from development to commercial deployment | Eliminates mid-program supplier change requiring revalidation under GMP frameworks |
| Innovation Nexus Pilot Lab | Translation of synthesis chemistries into commercial-ready workflows | Sunnyvale, California pilot facility reduces development-to-scale timeline for complex programs |
| More Than Threefold Coralville Capacity | High-volume MRD/NGS oligo production | Iowa manufacturing facility addresses supply continuity for commercial multi-client programs |
Labs should confirm that the supplier can provide lot-specific quality data, coupling efficiency records, and sequence verification reports compatible with CMC or IND submission requirements. Jennifer Meade, president, IDT, explains: “Our customers’ programs cannot compromise on speed, complexity, quality, or scale. IDT is creating a broader capability set; and a full-spectrum synthesis offering to address scientific and operational requirements customers need to move with greater speed, confidence, and continuity as they scale; and flexibility to leverage the right solution at every stage.”
Which Sectors Does This DNA Synthesis Expansion Affect Most?
This expansion is most immediately relevant to oncology labs, IVDR/CE-IVD diagnostic producers, and NGS service labs.
- Oncology Labs: Pharmacology and drug development labs managing ctDNA and multi-cancer detection panels rely on high-diversity pools, requiring strict lot-to-lot reproducibility for audit compliance.
- Diagnostic Assay Reagent Producers Under In Vitro Diagnostic Regulation (IVDR) or CE-marked In Vitro Diagnostic (CE-IVD): Changing suppliers during commercialization triggers new design verification and analytical validation cycles.
- Next-Generation Sequencing Service Labs: High-diversity capture panels for MRD depend directly on oligo pool uniformity and synthesis accuracy.
- siRNA & ASO Drug Programs: Require validated custom oligo supply for both research reagents and GMP-grade drug substances.
How to Assess Your Oligonucleotide Synthesis Supplier Strategy
Consolidating custom oligo production into a single provider reduces total cost of ownership and eliminates the dual-supplier audit burden. QA teams should verify that IDT’s documentation package for the new low-yield, high-diversity offering matches the lot-release data standards of its established GMP* catalog, particularly for programs that will need that data in an IND or biologics license application (BLA) submission. Reviewing existing supplier qualification records and revalidation thresholds before any transition is the appropriate first step.
The original press release can be found here.
This article was created with the assistance of Generative AI and has undergone editorial review before publishing.